ZyVersa Therapeutics, Inc. announced publication of an article in the peer-reviewed journal, Metabolism, which supports the mechanism of action of Cholesterol Efflux Mediator VAR 200 in development to treat kidney diseases. In the paper titled, "ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease," the authors reported that ABCA1 deficiency contributes to injury and dysfunction of the kidney's filtration system (glomerular endothelium) in early diabetic kidney disease ("DKD"). They proposed that ABCA1 transporter deficiency results in glomerular cholesterol/lipid accumulation leading to inflammation and cell death.

This causes structural and functional damage to the kidney's filtration systems and in turn, protein spend into the urine (proteinuria) and DKD progression. The authors concluded that therapies which effectively reduce elevated glomerular cholesterol levels have potential to combat early DKD.